InvestorsHub Logo
Post# of 252196
Next 10
Followers 15
Posts 1749
Boards Moderated 0
Alias Born 08/12/2007

Re: oc631 post# 156538

Thursday, 02/07/2013 11:04:55 PM

Thursday, February 07, 2013 11:04:55 PM

Post# of 252196

For the sickest [GT3] patients the "new" option will be Sofo/PegRiba.





After reviewing the design of interferon-based NEUTRINO it's becoming clear GILD is a company that places profits above patient health. My suggestion that GT3 patients could use Sofo/PegRiba as a "new" option in 2014 isn't credible because GILD chose to intentionally exclude GT2 and GT3 patients from the NEUTRINO study.


Q: Why would GILD exclude GT2/GT3 and test GT1,4,5,6 in the NEUTRINO study?*


The design of this Phase-3 study is appalling even before we knew Sofo/Riba [oral] would only work in half of GT3 patients. Instead of giving all HCV patients the option of using Sofo/PegRiba as a second-line therapy they wrote GT2/GT3 patients out of the design. This design denies GT2 and GT3 treatment-failure patients early access to this interferon-based option which would work incredibly well in these two genotypes. Perhaps too well.


Now the oral GT3 option is a failure with nothing to fall back on.






*If someone on this MB or from Gilead Sciences can answer the question above I'm open to listening.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.